Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Severe mental illness and European COVID-19 vaccination strategies

The EU advises prioritising vaccination for people whose health makes them particularly at risk for severe COVID-19, but leaves it to member states to decide which medical conditions get prioritised. Ethical, neuroscientific, and public health considerations have been used to prioritise individuals with severe mental illness (ie, psychotic disorders, bipolar disorders, and severe major depressive disorders).1–3 We systematically reviewed national COVID-19 vaccine deployment plans across 20 European countries (appendix pp 1–2).

Eight of 20 countries explicitly mentioned psychiatry or mental illness in their national vaccine strategy documents. Several countries prioritised institutional residents, which can include people with severe mental illness (table). Only four countries (Denmark, Germany, the Netherlands, and the UK) had some form of higher vaccination priority for outpatients with severe mental illness. Additionally, Latvia, Romania, Spain, and Sweden prioritised outpatients with disabilities, possibly including severe mental illness, whereas the Czech Republic and Sweden specified behavioural or mental problems interfering with pandemic regulation adherence as priority indication.

A European Centre for Disease Control and Prevention survey found that most European countries used a combination of epidemiological data, mathematical modelling, guidelines, ethical considerations, and published research to define specific morbidities for vaccine prioritisation.4 Here, we present four examples (from the Netherlands, UK, Denmark, and Germany) of different approaches that have positive outcomes for severe mental illness.

First, the UK used an Oxford University evidence-based algorithm to calculate the number of vaccinations needed to prevent one death.5 Importantly, this QCovid algorithm (University of Oxford, UK), based on UK data from Jan 24 to June 30, 2020, explicitly includes severe mental illness among its risk predictors, and so does the UK vaccination strategy. However, preliminary data (which had not been peer reviewed as of Feb 11, 2021) suggest that vaccination coverage for patients with severe mental illness is lagging behind that of other comorbidity groups.6

Denmark, Germany, and the Netherlands initially omitted mental disorders from their COVID-19 vaccination strategies. After a large nationwide Danish cohort study found that an increased risk for 30-day mortality was associated with severe mental illness (adjusted OR 2.5, 95% CI 1.2–5.1) and use of antipsychotics (adjusted OR 3.3, 95% CI 2.3–4.8),7 the Danish Health Authority urged health-care practitioners to refer for priority vaccination patients with psychotic disorders and other individuals with complex severe mental illness deemed to be at particularly high risk by the treating physician. Similarly, the Netherlands increased prioritisation of patients with severe mental illness following advocacy from mental health associations.8

The German federal research institute performed an umbrella review of published systematic reviews and meta-analyses to inform the federal Ministry of Health’s selection of risk comorbidities.9 However, evidence on psychiatric morbidity had not yet been systematically summarised at that time and was therefore not

References

1 Fried EI, Flake JK. Measurement matters. 2018. https://www.psychologicalscience.org/observer/measurement-matters (accessed May 29, 2020)
2 Wahl I, Lowe B, Bjorner JB, et al. Standardization of depression measurement: a common metric was developed for 11 self-report depression measures. J Clin Epidemiol 2014; 67: 73–86.
3 Puhan MA, Soesoeto I, Guyatt GH, Schünemann HJ. Combining scores from different patient reported outcome measures in meta-analyses: when is it justified? Health Qual Life Outcomes 2006; 4: 94.
4 Nature. Reality check on reproducibility. Nature 2016; 533: 437.
5 Weiss Dj, Kingsbury GG. Application of computerized adaptive testing to educational problems. J Educ Meas 1984; 21: 361–75.
6 Linden WJ, van der Linden WJ, Glas CA. Computerized adaptive testing: theory and practice. New York, NY: Springer, 2000.
7 Stochl J, Böhneke J, Pickett KE, Croudace TJ. Computerized adaptive testing of population psychological distress: simulation-based evaluation of GHQ-30. Soc Psychiatry Psychiatr Epidemiol 2016; 51: 895–906.
8 Stochl J, Böhneke J, Pickett KE, Croudace TJ. An evaluation of computerized adaptive testing for general psychological distress: combining GHQ-12 and Affectometer-2 in an item bank for public mental health research. BMC Med Res Methodol 2016; 16: 58.
| National documentation | Cardiovascular | Metabolic | Lung | Immune system | CNS | Other |
|------------------------|----------------|-----------|------|---------------|-----|-------|
| Mentions psychiatry or mental illness | Priority for institutionalised people (aged <65 years) | List of risk comorbidities specified | Hypertension | Diabetes mellitus | Chronic kidney disease | Chronic liver disease | Chronic pulmonary disease | Auto-immune disease | Immune-compromised conditions (eg, asplenia) | Post-transplant | Cerebrovascular disease | Chronic neurological or neuromuscular illness | Severe mental illness | Down syndrome |
| Effect sizes | 1.09 (0·94–1·26) | 1.32 (1·21–1·44) | 1.55 (1·35–1·79) | 1.74 (1·09–2·76) | 1.89 (1·18–3·05) | HR 1·19 (1·06–1·33) | RR 1·39 (1·13–1·70) | 4·20 (1·60–11·40) | 1·44 (0·90–2·30) | HR 1·38 (1·08–1·28) | 2·9 (1·3–6·6) | NA |
| Belgium | 1 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 2 |
| Czech Republic | 0 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Denmark | 1 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Finland | 0 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| France | 1 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Germany | 1 | 1 | Yes | Tier 2 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 2 | Tier 2 | Tier 1 |
| Greece | 0 | 1 | No | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Ireland | 0 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Italy* | 0 | 0 | No | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Latvia | 0 | 1 | Yes | Tier 2 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 2 | Tier 1 | Tier 1 | Tier 1 |
| Malta | 1 | 1 | No | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Netherlands | 1 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Norway | 0 | 0 | Yes | Tier 2 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Poland | 0 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Portugal | 0 | 1 | Yes | Tier 2 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Romania | 0 | 0 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Spain | 1 | 1 | No | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Sweden† | 0 | 1 | Yes | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| Turkey | 0 | 1 | No | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |
| UK | 1 | 0 | Yes | Tier 2 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 | Tier 1 |

Risk comorbidities selected for priority vaccination and their effect sizes (95% CI) for COVID-19 associated mortality risk. For full table of comorbidities see appendix p 3. Tier 1 is highest priority risk comorbidities. Tier 2 is priority risk comorbidities. Effect sizes for COVID-19 mortality in risk comorbidities were adapted from umbrella review by Robert Koch Institut for the German national vaccination strategy, (literature search done Dec 11, 2020, and published Jan 29, 2021). Effect sizes are OR, adjusted for at least the age of the study participants, unless otherwise specified. Empty cells show that this particular medical condition has not been specified as eligible for priority vaccination (ie, the strategy does not mention it). Two of 20 Italian regions (Sicilia and Veneto) are giving priority to residents in care centers for people with disability and mental illness. Besides people with a disease or condition involving an increase in risk, Sweden also prioritises a broader group of people with a condition that involves difficulties in following advice on infectious disease control measures; this applies to people aged 18–59 years with dementia and cognitive or mental impairment; this also applies to people living in socially vulnerable situations.

Table: Policies and risk comorbidities specified in national COVID-19 vaccination strategies
included in the original strategy. Following an update of its literature review, in which severe mental illness was found to be one of the few medical comorbidities with OR more than 2·0 for COVID-19 hospitalisation and mortality, the new strategy now explicitly includes severe mental illness in the highest risk group of medical comorbidities.9

Multiple high-quality studies have shown odds ratios for comorbid severe mental illness, and schizophrenia in particular, to be equal or even surpass those of other risk comorbidities included for prioritisation (table).124 Evidence-based policy would then require severe mental illness to be included in the list of risk comorbidities. Yet several sources of bias may have caused the risks associated with severe mental illness to be overlooked by most countries. Mental disorders are often not included as predictors in COVID-19 outcome studies. Studies specifically investigating the risks of psychiatric comorbidity have not yet been summarised in systematic reviews or meta-analyses and were therefore ignored by some national strategies and mathematical models.

Information collected in our report is not definitive or exhaustive. Countries are still developing vaccination plans and strategies can change as knowledge evolves. EU member states have been asked to share best practices for prioritisation through the Health Security Committee, coordinated by the European Commission.

In summary, European countries’ vaccination strategies try to balance ethical and scientific evidence, but for individuals with severe mental illness an evidence-policy disconnect remains. Most of these patients are treated in the community, and are currently overlooked by the majority of European COVID-19 vaccination strategies. Our joint recommendations, representing professionals, patients, and families, are clear and urgent: explicit inclusion of both inpatients and outpatients with severe mental illness in priority groups for COVID-19 vaccination, meaningful patient and family organisational participation in developing vaccination plans, and engagement of peer workers in providing vaccination education to patients. We therefore call on the European authorities (Council, Parliament, and Commission), national health authorities, and the scientific community to take note of the summarised evidence and our recommendations, and to correct this intolerable inequality.

This paper has been developed collaboratively and has received endorsements from the European College of Neuropsychopharmacology, European Psychiatric Association, European Federation of Associations of Families of People with Mental Illness, Global Alliance of Mental Illness Advocacy Networks-Europe, and European Union of Medical Specialists, Section of Psychiatry. The authors would like to express their utmost gratitude to our network of local representatives who helped to identify, collect and review the national strategy documents, and provided additional information derived from their personal clinical experience and the national psychiatric associations: Pavel Trancik (Czech Republic), Paula Mustonen (Finland), Joris Rauch (Germany), Thanos Kanellopoulos (Greece), Zetti Azveer (Ireland), Liene Berze (Latvia), Giovanni Grech (Malta), Morten Svendal Hatlen (Norway), Miguel Baguço (Portugal), Celso Arango and Eduard Vieta (Spain), Stanko Medic, Amelie Kjellström, and Tove Mogren (Sweden). LJP is a member of the European College of Neuropsychopharmacology Immunopsychiatry Thematic Working Group and the European Psychiatrists Association Committee on Education. LJP reports grants from Boehringer-Ingelheim and Janssen R&D, outside the submitted work. MCD is vice president for Continuing Medical Education at the European Union of Medical Specialists, Section of Psychiatry. CMP received research and consultancy funding from Johnson & Johnson (2012–18) and Boehringer Ingelheim (2020) and is funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer’s Disease consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck, and Pfizer, outside the submitted work. CMP is also funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and King’s College London, and by a NIHR Senior Investigator Award. PF-P reports personal fees from Menarini, Angelini, and Lundbeck, outside the submitted work. ML reports personal fees from Janssen and Sanofi; grants from Otsuka, Lundbeck, and Roche, outside the submitted work. All other authors declare no competing interests.

*Livia J De Picker, Marisa Casanova Dias, Michael E Benros, Benedetta Vai, Igor Branchi, Francesco Benedetti, Alessandra Borsini, Juan Carlos Leza, Hilika Karkräinen, Miia Männikkö, Carmine M Pariante, Ekin Sonmez Güngör, Anna Szczegielniak, Ryad Tamouza, Afra van der Markt, Paolo Fusar-Poli, Julian Beezhold, Marion Leboyer

livia.depicker@uantwerp.be

Scientific Initiative for Neuropsychiatric and Psychopharmacological Studies, University Psychiatric Hospital Campus Duffel, Duffel, Belgium (LJP); Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium (LJP); National Centre for Mental Health, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK (MCD); Section of Women’s Mental Health (MCD) and Department of Psychological Medicine (AB, CMP) and Department of Psychiatry Studies (PF-P) Institute of Psychiatry, Psychology and Neurosciences, King’s College London, London, UK; Copenhagen Research Centre for Mental Health, Copenhagen University Hospital, Copenhagen, Denmark (MEB), Department of Immunology & Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (MEB); Psychiatry & Clinical Psychology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy (BV, FB), Fondazione Centro San Raffaele, Milan, Italy (BV), Center for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy (BV), Psychiatry and Clinical Psychobiology Unit, University Vita-Salute San Raffaele, Milan, Italy (FB), Department of Pharmacology & Toxicology, Faculty of Medicine, Universidad Complutense Madrid, CIBERSAM, Madrid, Spain (JCL); Global Alliance of Mental Illness Advocacy Networks-Europe, Brussels, Belgium (HK); European Federation of Associations of Families of People with Mental Illness, Leuven, Belgium (MM); University of Western Health and Neurological Diseases Training and Research Hospital, Istanbul, Turkey (ESS), Department of Psychiatric Rehabilitation, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland (AS); IMRB Translational Neuropsychiatry Lab, Université Paris Est Créteil, Créteil, France (RT, ML), Department of Psychiatry and Addictology, Hopitaux Universitaires Henri Mondor, Créteil, France (RT, ML); Fondation FondaMental, Creteil, France (RT, ML); Amsterdam UMC, Vrije Universiteit Amsterdam, Psychiatry, Amsterdam Public Health Research Institute, The Netherlands (AvdM); Department of Brain and Behavioral Sciences, University of Pavia, Pavia,
De Hert M, Mazereel V, Detraux J, Van Assche K. Prioritising COVID-19 vaccination for people with severe mental illness. World Psychiatry 2021; 20: 54–55.

De Picker L, Yolken R, Benedetti F, et al. European COVID-19 exit strategy for people with severe mental disorders: too little, but not yet too late. Brain Behav Immun 2021; published online Jan 23. https://doi.org/10.1016/j.bbi.2021.01.008.

Warren N, Koeley S, Siskind D. Maximising the uptake of a COVID-19 vaccine in people with severe mental illness: a public health priority. JAMA Psychiatry 2020; published online Dec 15. https://10.1001/jamapsychiatry.2020.4396.

European Centre for Disease Prevention and Control. Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK. Dec 2, 2020. https://www.ecdc.europa.eu/en/publications-data/overview-current-eu-eea-uk-plans-covid-19-vaccines (accessed Jan 14, 2021).

Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020; 371: m3731.

Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020; 371: m3731.

MacKenna B, Curtis HJ, Morton CE, et al. Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23 4 million patients using OpenSAFELY. medRxiv 2021; published online Jan 26. https://www.medrxiv.org/content/10.1101/2021.01.25.21250356v1 (preprint).

Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol 2020; 49: 1468–81.

De Jonge H. Kamerbrief over COVID-19 vaccinatiestrategie update stand van zaken: Minister De Jonge geeft een update over de stand van zaken van de COVID-19 vaccinatiestrategie. Jan 4, 2021. https://www.rijksoverheid.nl/documenten/kamerstukken/2021/01/04/kamerbrief-over-covid-19-vaccinatiestrategie-update-stand-van-zaken (accessed Jan 7, 2021).

Robert Koch Institut. Epidemiologisches bulletin 5/2021. 2021. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/05_21.pdf (accessed Feb 15, 2021).

Nemani K, Li C, Olsson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry 2021; published online Jan 27. https://10.1001/jamapsychiatry.2020.442.